The Ink4a tumor suppressor gene product, p19(Arf), interacts with MDM2 and neutralizes MDM2's inhibition of p53

Cell

Volumn 92, Issue 6, 1998, Pages 713-723

  Pomerantz, Jason ^a   Schreiber Agus, Nicole ^a   Liégeois, Nanette J ^a   Silverman, Adam ^a   Alland, Leila ^a   Chin, Lynda ^a   Potes, Jason ^a   Chen, Ken ^a   Orlow, Irene ^b   Lee, Han Woong ^a,c   Cordon Cardo, Carlos ^b   DePinho, Ronald A ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c Seoul National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; PROTEIN P53;

ARTICLE; CANCER; CARCINOGENESIS; GENE CONTROL; GROWTH INHIBITION; HUMAN; PRIORITY JOURNAL; PROTEIN DNA INTERACTION; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

EID: 0032549704     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0092-8674(00)81400-2     Document Type: Article

References (67)

1. Alland, L., Muhle, R., Hou, H., Jr., Potes, J., Chin, L., Schreiber-Agus, N., and DePinho, R.A. (1997). Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression. Nature 387, 49-55.
2. Barak, Y., Gottlieb, E., Juven-Gershon, T., and Oren, M. (1994). Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. Genes Dev. 8, 1739-1749.
3. Bartkova, J., Lukas, J., Guldberg, P., Alsner, J., Kirkin, A.F., Zeuthen, J., and Bartek, J. (1996). The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res. 56, 5475-5483.
4. ARF in breast cancer. Clin. Cancer Res. 2, 1993-1998.
5. Brown, D.R., Deb, S., Munoz, R., Subler, M., and Deb, S.P. (1993). The tumor suppressor p53 and the oncoprotein simian virus 40 T antigen bind to overlapping domains on the MDM2 protein. Mol. Cell. Biol. 13, 6849-6857.
6. Cahilly-Snyder, L., Yang-Feng, T., Francke, U., and George, D.L. (1987). Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somat. Cell Mol. Genet. 13, 235-244.
7. Chen, J.D., Lin, J.Y., and, Levine, A.J. (1995). Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene. Mol. Med. 1, 141-142.
8. Chin, L., Pomerantz, J., Polsky, D., Jacobson, M., Cohen, C., Cordon-Cardo, C., Horner, J.W., and DePinho, R.A. (1997). Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev. 11, 2822-2834.
9. Cordon-Cardo, C. (1995). Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. Am. J. Pathol. 147, 545-560.
10. Crook, T., Marston, N.J., Sara, E.A., and Vousden, K.H. (1994). Transcriptional activation by p53 correlates with suppression of growth but not transformation. Cell 79, 817-827.
11. El-Deiry, W.S., Tokino, T., Velculescu, V.E., Levy, D.B., Parsons, R., Trent, J.M., Lin, D., Mercer, W.E., Kinzler, K.W., and Vogelstein, B. (1993). WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817-825.
12. Eliyahu, D., Michalovite, D., Eliyahu, S., Pinhasi-Kimhi, O., and Oren, M. (1989). Wild-type p53 can inhibit oncogene-mediated focus formation. Proc. Natl. Acad. Sci. USA 86, 8763-8767.
13. Elledge, S.J., Winston, J., and Harper, J.W. (1996). A question of balance: the role of cyclin-kinase inhibitors in development and tumorigenesis. Trends Biochem. Sci. 6, 388-392.
14. Fakharzadeh, S.S., Trusko, S.P., and George, D.L. (1997). Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J. 10, 1565-1569.
15. Fanning, E. (1992). Simian virus 40 large T antigen: the puzzle, the pieces, and the emerging picture. J. Virol. 66, 1289-1293.
16. Finlay, C.A. (1993). The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol. Cell. Biol. 13, 301-306.
17. Finlay, C.A., Hinds, P.W., and Levine, A.J. (1989). The p53 protooncogene can act as a suppressor of transformation. Cell 57, 1083-1093.
18. Gorman, C.M., Moffat, L.F., and Howard, B.H. (1982). Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol. Cell. Biol. 2, 1044-1051.
19. Gottlieb, T.M., and Oren, M. (1996). p53 in growth control and neoplasia. Biochim. Biophys. Acta. 1287, 77-102.
20. Gruis, N.A., Weaver-Feldhaus, J., Liu, Q., Frye, C., Eeles, R., Orlow, I., Lacombe, L., Ponce-Castaneda, V., Lianes, P., Latres, E., et al. (1995). Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression. Am. J. Pathol. 146, 1199-1206.
21. INK4A/CDKN2, MTS2/p15INK4B, p53, and Rb genes in primary lymphoid malignancies. Blood 87, 4949-4958.
22. Haupt, Y., Maya, R., Kazaz, A., and Oren, M. (1997). Mdm2 promotes the rapid degradation of p53. Nature 387, 296-299.
23. Hawley-Nelson, P., Vousden, K.H., Hubbert, N.L., Lowy, D.R., and Schiller, J.T. (1989). HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J. 8, 3905-3910.
24. Heinzel, P.A., Balaram, P., and Bernard, H.U. (1996). Mutations and polymorphisms in the p53, p21 and p16 genes in oral carcinomas of Indian betel quid chewers. Int. J. Cancer 68, 420-423.
25. Henning, W., Rohaly, G., Kolzau, T., Knippschild, U., Maacke, H., and Deppert, W. (1997). MDM2 is a target of simian virus 40 in cellular transformation and during lytic infection. J. Virol. 71, 7609-7618.
26. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C.C. (1991). p53 mutations in human cancers. Science 253, 49-53.
27. Jacks, T. (1994). Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4, 1-7.
28. Jones, S.N., Roe, A.E., Donehower, L.A., and Bradley, A. (1995). Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378, 206-208.
29. Kamb, A., Gruis, N.A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S.V., Stockert, E., Day, R.S., III, Johnson, B.E., and Skolnick, M.H. (1994). A cell cycle regulator potentially involved in genesis of many tumor types. Science 264, 436-440.
30. ARF. Cell 91, 649-659.
31. INK4 and retinoblastoma protein status in non-small cell lung cancer: potential synergistic effect with altered p53 protein on proliferative activity. Cancer Res. 56, 5557-5562.
32. Ko, L.J., and Prives, C. (1996). p53: puzzle and paradigm. Gene Dev. 10, 1054-1072.
33. Kubbutat, M.H., Jones, S.N., and Vousden, K.H. (1997). Regulation of p53 stability by Mdm2. Nature 387, 299-303.
34. Kussie, P.H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A.J., and Pavletich, N.P. (1996). Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274, 948-953.
35. Lahoz, E.G., Xu, L., Schreiber-Agus, N., and DePinho, R.A. (1997). Suppression of Myc, but not E1a, transformation activity by Max-associated proteins, Mad and Mxi1. Proc. Natl. Acad. Sci. USA 91, 5503-5507.
36. Land, H., Parada, L.F., and Weinberg, R.A. (1983). Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 304, 596-602.
37. Levine, A.J. (1997). p53, the cellular gatekeeper for growth and division. Cell 88, 323-331.
38. Levine, A.J., Momand, J., and Finlay, C.A. (1991). The p53 tumor suppressor gene. Nature 351, 453-456.
39. Lukas, J., Perry, D., Aagaard, L., Mann, D.J., Bartkova, J., Strauss, M., Peters, G., and Bartek, J. (1995). Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature 375, 503-506.
40. Mahon, K.A., Chepelinsky, A.B., Khillan, J.S., Overbeek, P.A., Piatigorsky, J., and Westphal, H. (1987). Oncogenesis of the lens in transgenic mice. Science 235, 1622-1628.
41. Medema, R.H., Herrera, R.E., Lam, F., and Weinberg, R.A. (1995). Growth suppression by p16 Ink4 requires functional retinoblastoma protein. Proc. Natl. Acad. Sci. USA 92, 6289-6293.
42. Momand, J., Zambetti, G.P., Olson, D.C., George, D., and Levine, A.J. (1992). The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69, 1237-1245.
43. Morgenbesser, S.D., Williams, B.O., Jacks, T., and DePinho, R.A. (1994). p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens. Nature 371, 72-74.
44. Munger, K., Phelps, W.C., Bubb, V., Howley, P.M., and Schlegel, R. (1989). The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J. Virol. 63, 4417-4421.
45. INK4 (9p21), and DBM (13q14) in B-cell chronic lymphocytic leukemia. Mol. Carcinog. 14, 141-146.
46. Oliner, J.D., Kinzler, K.W., Meltzer, P.S., George, D.L., and Vogelstein, B. (1992). Amplification of a gene encoding a p5-associated protein in human sarcomas. Nature 358, 80-83.
47. Oliner, J.D., Pietenpol, J.A., Thiagalingam, S., Gyuris, J., Kinzler, K.W., and Vogelstein, B. (1993). Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362, 857-860.
48. Olson, D.C., Marechal, V., Momand, J., Chen, J., Romocki, C., and Levine, A.J. (1993). Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes. Oncogene 8, 2353-2360.
49. Pietenpol, J.A., Tokino, T., Thiagalingam, S., El-Deiry, W.S., Kinzler, K.W., and Vogelstein, B. (1994). Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc. Natl. Acad. Sci. USA 91, 1998-2002.
50. INK4b genes. Oncogene 11, 635-645.
51. Quelle, D.E., Zindy, F., Ashmun, R.A., and Sherr, C.J. (1995b). Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83, 993-1000.
52. Quelle, D.E., Cheng, M., Ashmun, R.A., and Sherr, C.J. (1997). Cancer-associated mutations at the INK4a locus cancel cell cycle arrest by p16INK4a but not by the alternative reading frame protein p19ARF. Proc. Natl. Acad. Sci. USA 94, 669-673.
53. Schreiber-Agus, N., Chin, L., Chen, K., Torres, R., Thomson, C.T., Sacchettini, J.C., and DePinho, R.A. (1994). Evolutionary relationships and functional conservation among vertebrate Max-associated proteins: the zebrafish homolog of Mxi1. Oncogene 9, 3167-3177.
54. Schreiber-Agus, N., Chin, L., Chen, K., Torres, R., Rao, G., Guida, P., Skoultchi, A.I., and DePinho, R.A. (1995). An amino-terminal domain of Mxi1 mediates anti-Myc oncogenic activity and interacts with a homolog of the yeast transcriptional repressor SIN3. Cell 80, 777-786.
55. Schreiber-Agus, N., Chin, L., Chen, K., Torres, R., Rao, G., Guida, P., Skoultchi, A.I., and DePinho, R.A. (1997). An amino-terminal domain of Mxi1 mediates anti-Myc oncogenic activity and interacts with a homolog of the yeast transcriptional repressor SIN3. Cell 80, 777-786.
56. Serrano, M., Hannon, G.J., and Beach, D. (1993). A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/cdk4. Nature 366, 704-707.
57. INK4. Science 267, 249-252.
58. Serrano, M., Lee, H., Chin, L., Cordon-Cardo, C., Beach, D., and DePinho, R.A. (1996). Role of the INK4a locus in tumor suppression and cell mortality. Cell 85, 27-37.
59. Sherr, C.J. (1996). Cancer cell cycles. Science 274, 1672-1676.
60. Symonds, H., Krall, K., Remington, L., Saenz-Robles, M., Lowe, S., Jacks, R., and Van Dyke, T. (1994). p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 78, 703-711.
61. Thut, C.J., Goodrich, J.A., and Tjian, R. (1997). Repression of p53-mediated transcription by MDM2: a dual mechanism. Genes Dev. 11, 1974-1986.
62. Van Dyke, T.A. (1994). Analysis of viral-host protein interactions and tumorigenesis in transgenic mice. Semin. Cancer Biol. 5, 47-60.
63. Weinberg, R.A. (1995). The retinoblastoma protein and cell cycle control. Cell 81, 323-330.
64. Williams, B.O., Remington, L., Albert, D.M., Mukai, S., Bronson, R.T., and Jacks, T. (1994). Cooperative tumorigenic effects of germline mutations in Rb and p53. Nature Genet. 7, 480-484.
65. Xiao, Z.X., Chen, J., Levine, A.J., Modjtahedi, N., Xing, J., Sellers, W.R., and Livingston, D.M. (1995). Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 375, 694-698.
66. Zhang, Y., Xiong, Y., and Yarbrough, W.G. (1998). ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92, this issue, 725-734.
67. INK4a binding domain of CDK4 in familial melanoma. Nature Genet. 12, 97-99.